{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:48:06Z","timestamp":1792788486184,"version":"4.5.0"},"reference-count":42,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) benefit patients with diabetes mellitus (DM) and obesity. While contraindicated in medullary thyroid cancer, their effect in well-differentiated thyroid cancer (DTC) remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the impact of GLP-1RAs on the risk of DTC recurrence\/progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Setting<\/jats:title>\n                    <jats:p>Retrospective observational cohort study at a tertiary care center in New York.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants, Intervention, and Main Outcome<\/jats:title>\n                    <jats:p>Five hundred thirty-six patients with DTC exposed to GLP-1RA were matched 1:1 to 536 patients with DTC never exposed to GLP-1RA by age, date of DTC diagnosis, TNM stage, body mass index (BMI), and DM. A multistate model enabled us to assess the impact of GLP-1RA as a time-dependent variable on the transition of patients with DTC from a \u201cno\/stable disease\u201d state to a \u201crecurrence\/progression\u201d state.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1072 patients, median age 49, 71% females, 54% with DM, mean BMI \u00b1 SD 35 \u00b1 7 kg\/m\u00b2, 84% with American Joint Committee on Cancer stage I disease, 58% with American Thyroid Association (ATA) intermediate or high risk of recurrence, with median GLP-1RA exposure of 16 months were followed for a median of 69 months. GLP-1RA use was not significantly associated with recurrence or progression of disease in the survival cohort [hazard ratio (HR) = 0.87, 95% confidence interval (CI) 0.62-1.21, P = .39) or the entire cohort (HR = 0.75, 95% CI 0.54-1.03, P = .07) on a multivariable model adjusted for age, ATA risk, radioactive iodine therapy, and DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We did not find GLP-1RA to be significantly associated with recurrent\/progressive DTC. Eligible patients with DTC should not be denied the cardiometabolic benefits of GLP-1RA when clinically indicated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag051","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:43:41Z","timestamp":1770381821000},"page":"e1795-e1804","source":"Crossref","is-referenced-by-count":4,"title":["Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1090-4794","authenticated-orcid":false,"given":"Armando","family":"Patrizio","sequence":"first","affiliation":[{"name":"Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]},{"name":"Department of Medicine, University of Pisa , 56100 Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-6093","authenticated-orcid":false,"given":"Audrey","family":"Mauguen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Fagin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeez","family":"Farooki","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie S","family":"Fish","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0259-969X","authenticated-orcid":false,"given":"James","family":"Flory","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Newman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubaina","family":"Presswala","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona M","family":"Sabra","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Michael","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8852-1120","authenticated-orcid":false,"given":"Laura","family":"Boucai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"issue":"2","key":"2026061619571744700_dgag051-B1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"25","key":"2026061619571744700_dgag051-B2","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"2026061619571744700_dgag051-B3","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"3","key":"2026061619571744700_dgag051-B4","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation","volume":"153","author":"Madsen","year":"2012","journal-title":"Endocrinology"},{"issue":"3","key":"2026061619571744700_dgag051-B5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2337\/dc17-1956","article-title":"No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for up to 5 years in the LEADER trial","volume":"41","author":"Hegedus","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"2026061619571744700_dgag051-B6","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2337\/dc18-2028","article-title":"Changes in serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)","volume":"42","author":"Bethel","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"2026061619571744700_dgag051-B7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2011-2407","article-title":"Glucagon like peptide-1 receptor expression in the human thyroid gland","volume":"97","author":"Gier","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026061619571744700_dgag051-B8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3803\/EnM.2014.29.4.536","article-title":"Expression of glucagon-like peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance","volume":"29","author":"Jung","year":"2014","journal-title":"Endocrinol Metab"},{"issue":"2","key":"2026061619571744700_dgag051-B9","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"2026061619571744700_dgag051-B10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jcpt.13259","article-title":"Glucagon-like peptide-1 analogues and thyroid cancer: an analysis of cases reported in the European pharmacovigilance database","volume":"46","author":"Mali","year":"2021","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"2026061619571744700_dgag051-B11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s40261-022-01202-1","article-title":"Safety of glucagon-like peptide-1 receptor agonists: a real-world study based on the US FDA adverse event reporting system database","volume":"42","author":"Wu","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"8","key":"2026061619571744700_dgag051-B12","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026061619571744700_dgag051-B13","doi-asserted-by":"crossref","first-page":"e078225","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"issue":"1","key":"2026061619571744700_dgag051-B14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/thy.2024.0387","article-title":"Glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study","volume":"35","author":"Baxter","year":"2025","journal-title":"Thyroid"},{"issue":"2","key":"2026061619571744700_dgag051-B15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2012.09.008","article-title":"A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer","volume":"98","author":"Alves","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"2026061619571744700_dgag051-B16","doi-asserted-by":"crossref","first-page":"927859","DOI":"10.3389\/fendo.2022.927859","article-title":"Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials","volume":"13","author":"Hu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2026061619571744700_dgag051-B17","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2337\/dc25-0154","article-title":"Risk of thyroid tumors with GLP-1 receptor agonists: a retrospective cohort study","volume":"48","author":"Morales","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061619571744700_dgag051-B18","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.2147\/OTT.S150701","article-title":"Effects of insulin analogs and glucagon-like peptide-1 receptor agonists on proliferation and cellular energy metabolism in papillary thyroid cancer","volume":"10","author":"He","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"7","key":"2026061619571744700_dgag051-B19","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2026061619571744700_dgag051-B20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/cancers17010078","article-title":"Differential effects of GLP-1 receptor agonists on cancer risk in obesity: a nationwide analysis of 1.1 million patients","volume":"17","author":"Levy","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2026061619571744700_dgag051-B21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/thy.2017.0102","article-title":"Updated American joint committee on cancer\/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why?","volume":"27","author":"Tuttle","year":"2017","journal-title":"Thyroid"},{"issue":"8","key":"2026061619571744700_dgag051-B22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"issue":"2","key":"2026061619571744700_dgag051-B23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.37737\/ace.22005","article-title":"Introduction to matching in case-control and cohort studies","volume":"4","author":"Iwagami","year":"2022","journal-title":"Ann Clin Epidemiol"},{"issue":"3","key":"2026061619571744700_dgag051-B24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2026061619571744700_dgag051-B25","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsboll","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2026061619571744700_dgag051-B26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2026061619571744700_dgag051-B27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12020-019-02055-z","article-title":"GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials","volume":"66","author":"Cao","year":"2019","journal-title":"Endocrine"},{"issue":"3","key":"2026061619571744700_dgag051-B28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamaoto.2024.4852","article-title":"GLP-1RA use and thyroid cancer risk","volume":"151","author":"Brito","year":"2025","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"9612","key":"2026061619571744700_dgag051-B29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"2026061619571744700_dgag051-B30","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2013viewpoint of the IARC working group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2026061619571744700_dgag051-B31","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jnci\/djz202","article-title":"Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995-2015)","volume":"112","author":"Kitahara","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2026061619571744700_dgag051-B32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1089\/thy.2021.0445","article-title":"Body mass index and thyroid cancer risk: a pooled analysis of half a million men and women in the Asia cohort consortium","volume":"32","author":"Shin","year":"2022","journal-title":"Thyroid"},{"issue":"18","key":"2026061619571744700_dgag051-B33","doi-asserted-by":"crossref","first-page":"22232","DOI":"10.18632\/aging.203529","article-title":"High prevalence of thyroid carcinoma in patients with insulin resistance: a meta-analysis of case-control studies","volume":"13","author":"Zhao","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"10","key":"2026061619571744700_dgag051-B34","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 Receptor agonists and cancer risk in adults with obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol"},{"issue":"3","key":"2026061619571744700_dgag051-B35","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1007\/s11357-024-01494-5","article-title":"Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types","volume":"47","author":"Ungvari","year":"2025","journal-title":"Geroscience"},{"issue":"14","key":"2026061619571744700_dgag051-B36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.14715\/cmb\/2023.69.14.37","article-title":"GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells","volume":"69","author":"Zhang","year":"2023","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"2","key":"2026061619571744700_dgag051-B37","first-page":"91","article-title":"Glucagon-like peptide-1 analogues inhibit proliferation and increase apoptosis of human prostate cancer cells in vitro","volume":"125","author":"Li","year":"2017","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"10","key":"2026061619571744700_dgag051-B38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31083\/j.fbl2810259","article-title":"The effect of liraglutide on lung cancer and its potential protective effect on high glucose-induced lung senescence and oxidative damage","volume":"28","author":"Pu","year":"2023","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"9","key":"2026061619571744700_dgag051-B39","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/dom.12291","article-title":"Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K\/Akt pathway","volume":"16","author":"Zhao","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2026061619571744700_dgag051-B40","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/clinem\/dgaf053","article-title":"Semaglutide reprograms macrophages via the GLP-1R\/PPARG\/ACSL1 pathway to suppress papillary thyroid carcinoma growth","volume":"110","author":"Wang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026061619571744700_dgag051-B41","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1089\/thy.2020.0272","article-title":"Real-world performance of the American Thyroid Association risk estimates in predicting 1-year differentiated thyroid cancer outcomes: a prospective multicenter study of 2000 patients","volume":"31","author":"Grani","year":"2021","journal-title":"Thyroid"},{"issue":"6","key":"2026061619571744700_dgag051-B42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000500773","article-title":"Performance of ATA risk stratification systems, response to therapy, and outcome in an Indian cohort of differentiated thyroid carcinoma patients: a retrospective study","volume":"8","author":"Ruben","year":"2019","journal-title":"Eur Thyroid J"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag051\/66923105\/dgag051.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/e1795\/66923105\/dgag051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/e1795\/66923105\/dgag051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:57:31Z","timestamp":1781654251000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/7\/e1795\/8487285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,15]]},"published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag051","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,15]]}}}